RAD1 forms the 9-1-1 complex with Rad9 and Hus1, which stabilizes DNA repair enzymes like FEN1 and DNA ligase I .
The complex is recruited to double-strand breaks (DSBs) during S phase, facilitating homologous recombination .
Sumoylation at lysine 32 (K32) regulates RAD1’s dissociation from DNA post-repair, enhancing efficiency in high-damage conditions .
Knockout studies in mice show that RAD1 deletion increases susceptibility to skin tumors (e.g., DMBA-induced papillomas) .
Overexpression of Rad9 (a binding partner) correlates with poor prognosis in ovarian and prostate cancers .
Jab1/CSN5-mediated degradation of the 9-1-1 complex suppresses checkpoint signaling, accelerating genomic instability .
DNA Repair Studies: Rad1 antibodies identify RAD1 localization at DSBs via IF/ICC .
Cancer Biomarker Screening: Used to correlate RAD1 expression levels with tumor progression .
Mechanistic Studies: Detect sumoylation or phosphorylation states in response to UV/CPT treatment .